Medical Treatment of Melanoma: Adjuvant and Neoadjuvant Therapies

The past few years have witnessed the practice-changing results of adjuvant clinical trials that have dramatically improved the outcomes of patients with resected, high-risk melanoma. After a 20-year era of adjuvant interferon, checkpoint inhibitor immunotherapy and BRAF+MEK inhibitors revolutionized the management of melanoma in everyday clinical practice. In this review, we summarize the current state of the art of the adjuvant treatment of high-risk melanoma, with a view on the future developments in the field such as the translation of these treatments into the neoadjuvant setting.